Federal health officials say AstraZeneca may have offered "outdated information" about its coronavirus vaccine.
In a statement Tuesday morning, the Data and Safety Monitoring Board said it was concerned the drug maker provided an "incomplete view" of efficacy data from a U.S. clinical trial.
On Monday, AstraZeneca reported its vaccine was 79% effective at preventing symptomatic cases of COVID-19.
The shot has been widely used outside the U.S., and the company plans to seek FDA approval in the coming weeks.
